PPCB.US Propanc Biopharma, Inc. Common Stock

Healthcare Biotechnology USA Stocks
1.79 USD
Close of Nov 17, 2026
1.63 315.00
Market cap
USD 1.88M
P/E
-
P/B
0.20x
ROE
-485.9%
Dividend yield
49.68%
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Sep 2026.

Is PPCB.US undervalued?

Graham number

The Graham number of Propanc Biopharma, Inc. Common Stock cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Propanc Biopharma, Inc. Common Stock fundamental analysis

No fundamental analysis for Propanc Biopharma, Inc. Common Stock yet.

Propanc Biopharma, Inc. Common Stock stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Propanc Biopharma, Inc. Common Stock

Propanc Biopharma, Inc., a development-stage biopharmaceutical healthcare company, engages in the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancers in Australia. Its lead product candidate is PRP, an intravenous injection proenzyme treatment designed as a therapeutic option in cancer treatment and prevention which has completed pre-clinical studies. The company has a research and collaboration agreement with the University of Jaén…

Full company profile